UK officials and researchers are positioning the country as a hub for mRNA-based biotechnology, highlighted by Moderna’s new facility and government support. This contrasts with recent U.S. policy shifts under Health Secretary Robert F. Kennedy Jr., including rescinded contracts and reduced funding for mRNA infectious disease research. The $16 million PRISM trial aims to validate AI-assisted mammography screening in breast cancer diagnostics, underscoring ongoing innovation in the UK even as U.S. prioritization wanes.